Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF and sVEGFR as a biomarker for subjects treated with sorafenib.

Abstract: The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of stanniocalcin as a biomarker for VEGFR2 inhibitors.

Abstract: The present invention is directed to the detection and quantification of total PDGFR-? in body fluids, particularly serial changes of total PDGFR-? levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-? in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.

Abstract: The invention relates generally to the use of certain substituted fused or unfused pyridazine or pyridine derivatives which are KDR inhibitors in combination with other chemotherapeutic agents for use in treatment of diseases associated with abnormal angiogenesis and/or hyperpermeability and/or hyperproliferative diseases, such as cancer.

Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by raf kinase and diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Abstract: The phenylcyclohexylcarboxamides, some of which are known, are suitable as active compounds in medicaments, in particular in medicaments for the treatment of restenosis.

Abstract: Substituted indole derivatives are prepared by reacting appropriate carboxylic acids, if appropriate in the presence of auxiliaries, with appropriate amines. The substituted indole derivatives are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and restenosis.

Abstract: Immunoassay methods useful for the determination of the presence or absence of CEA gene family members are provided. Methods are provided that differentiate between members of the CEA gene family. In addition, monoclonal antibodies against CEA-family members, said antibodies specific to TM-CEA, CEA, or NCA, and not cross-reactive with other CEA family members are provided. Further, antibodies specific to two of three CEA gene family member, TM-CEA and NCA but not CEA and CEA and NCA but not TM-CEA, TM-CEA and CEA but not NCA, are provided. Said monoclonal antibodies include antibodies against native protein and antibodies against denatured protein. Also provided are hybridoma cell lines secreting said antibodies, and pharmaceutical compositions containing said antibodies or fragments thereof.